Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells through ACE2 receptors, leading to coronavirus disease (COVID-19)-related pneumonia, while also causing acute myocardial injury and chronic damage to the cardiovascular system. Therefore, particular attention should be given to cardiovascular protection during treatment for COVID-19.
MeSH terms
- Angiotensin Receptor Antagonists / therapeutic use
- Angiotensin-Converting Enzyme 2
- Angiotensin-Converting Enzyme Inhibitors / therapeutic use
- Antiviral Agents / adverse effects
- Betacoronavirus
- COVID-19
- Cardiotoxicity
- Cardiovascular Diseases / complications*
- Cardiovascular Diseases / virology
- Cardiovascular System / pathology
- Cardiovascular System / virology*
- Coronavirus Infections / complications*
- Coronavirus Infections / physiopathology*
- Heart / virology
- Heart Diseases / virology*
- Humans
- Hypertension / complications
- Hypertension / drug therapy
- Myocardium / pathology
- Pandemics
- Peptidyl-Dipeptidase A / metabolism
- Pneumonia, Viral / complications*
- Pneumonia, Viral / physiopathology*
- Receptors, Virus / antagonists & inhibitors
- Receptors, Virus / metabolism
- SARS-CoV-2
Substances
- Angiotensin Receptor Antagonists
- Angiotensin-Converting Enzyme Inhibitors
- Antiviral Agents
- Receptors, Virus
- Peptidyl-Dipeptidase A
- ACE2 protein, human
- Angiotensin-Converting Enzyme 2